HR-8908-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Eric Sorensen (D-IL)
What it does
This bill would amend the Federal Food, Drug, and Cosmetic Act to strengthen the FDA's ability to deny citizen petitions that are primarily intended to delay the approval of generic drugs and biosimilars. It would impose a 60-day filing deadline from when a petitioner first learns of the relevant information, add specific criteria the FDA must consider when determining whether a petition is delay-motivated, require the FDA to refer suspected delay petitions to the Federal Trade Commission, and expand congressional reporting requirements to include detailed data on petition timing, resource costs, and any delays caused to generic drug approvals.
Who benefits
Patients who use generic drugs or biosimilars and would gain earlier access to lower-cost alternatives. Insurers and pharmacy benefit managers who pay for brand-name drugs while generics are delayed. Employers and government health programs (Medicare, Medicaid) that cover prescription drug costs. Generic and biosimilar drug manufacturers whose applications are held up by delay petitions. The FTC, which would receive referrals and gain a clearer enforcement pathway. Taxpayers who fund federal drug benefit programs.
Who is hurt
Brand-name pharmaceutical manufacturers who currently use citizen petitions as a legitimate tool to raise safety and scientific concerns about competing products — even good-faith petitions could face stricter scrutiny under the new standards. Patients and advocacy groups who rely on the citizen petition process to flag genuine safety issues with generic approvals. Attorneys and consultants who specialize in FDA regulatory petitions. Companies with complex patent portfolios who may have legitimate reasons to file petitions close to patent expiration dates.
Supporters argue
Supporters argue that brand-name drug companies have systematically abused the citizen petition process to extend monopoly pricing by months or years, costing patients and payers billions of dollars. They contend that a 2019 FDA analysis found that petitions filed within six months of a generic's expected approval date were denied at a significantly higher rate, suggesting delay — not safety — was the primary motive. The 60-day filing deadline and FTC referral requirement, they argue, create meaningful deterrents against strategic delay while preserving the petition process for genuinely safety-motivated submissions.
Opponents argue
Opponents argue that the citizen petition process is a critical safety valve that allows manufacturers, patient groups, and scientists to raise legitimate scientific concerns before a potentially unsafe generic reaches the market. They contend that the bill's "primary purpose" standard is vague and gives the FDA broad discretion to dismiss petitions without full review, and that the 60-day filing deadline may be unworkable for complex scientific issues that take time to fully develop. They further argue that mandatory FTC referrals could chill good-faith petitions by exposing filers to antitrust investigations even when their underlying safety concerns are valid.
Constitutional context
Congress has broad authority to regulate the drug approval process under the Commerce Clause (Art. I, §8, cl. 3) and the Necessary and Proper Clause. Post-Loper Bright (2024), courts will independently review FDA's interpretation of the "primary purpose of delay" standard rather than deferring to the agency, which could expose the bill's more discretionary provisions to heightened judicial scrutiny.
Checks and balances
The FDA (executive branch) gains expanded discretion to deny petitions and refer matters to the FTC; courts retain review authority over FDA petition denials, and Congress would receive expanded annual reports creating a legislative oversight mechanism.
Historical precedent
The FDA Amendments Act of 2007 first created the Section 505(q) citizen petition framework specifically to address delay tactics, but studies published after its enactment found that strategic late-filed petitions continued, prompting this further tightening of the rules.